ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

INCY Incyte Corporation

58.00
-0.37 (-0.63%)
Mar 18 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 1,811,550
Bid Price 56.71
Ask Price 59.39
News -
Day High 58.78

Low
50.27

52 Week Range

High
76.04

Day Low 57.30
Company Name Stock Ticker Symbol Market Type
Incyte Corporation INCY NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.37 -0.63% 58.00 20:00:00
Open Price Low Price High Price Close Price Prev Close
58.75 57.30 58.78 57.34 58.37
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
27,259 1,811,550 $ 58.16 $ 105,364,576 - 50.27 - 76.04
Last Trade Time Type Quantity Stock Price Currency
19:05:31 formt 100 $ 58.00 USD

Incyte (INCY) Options Flow Summary

Overall Flow

Bearish

Net Premium

-26k

Calls / Puts

0.00%

Buys / Sells

100.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

Incyte Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
12.88B 224.53M - 3.7B 597.6M 2.66 21.55
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Incyte News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No INCY Message Board. Create One! See More Posts on INCY Message Board See More Message Board Posts

Historical INCY Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week60.1561.1657.3059.062,260,984-2.15-3.57%
1 Month57.7961.86557.3059.431,871,8680.210.36%
3 Months63.1067.36556.1060.601,689,913-5.10-8.08%
6 Months59.8067.36550.2758.571,832,684-1.80-3.01%
1 Year73.5376.0450.2762.061,789,326-15.53-21.12%
3 Years79.3688.2650.2770.311,625,842-21.36-26.92%
5 Years84.82111.0550.2775.831,506,440-26.82-31.62%

Incyte Description

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Your Recent History

Delayed Upgrade Clock